Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-25

FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (SpecGx LLC)

View source ↗

Summary

FDA approved a supplemental application for dextroamphetamine sulfate from SpecGx LLC, approving a generic formulation of the ADHD/narcolepsy stimulant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dextroamphetamine sulfate (dextroamphetamine sulfate)

Snippet

SUPPL AP for DEXTROAMPHETAMINE SULFATE (DEXTROAMPHETAMINE SULFATE)